Literature DB >> 1533543

Early T-cell defects in pre-type 1 diabetes.

L al Sakkaf1, P Pozzilli, P J Bingley, M W Lowdell, J M Thomas, E Bonifacio, E A Gale, G F Bottazzo.   

Abstract

Alterations of lymphocyte subsets have been recently reported in pre-type 1 diabetes but the relation with other immunological markers, in particular islet cell antibodies (ICA), is still unknown. In the present study, we have investigated prospectively changes of lymphocyte subsets in 86 first-degree relatives of patients affected by type 1 diabetes and correlated such modifications with ICA titres. Among individuals with persistent ICA, 8 had ICA titres of more than 20 JDF units, 14 had ICA titres between 5 and 20 JDF units and 64 had ICA titres between 0 and 5 JDF units. First-degree relatives with ICA titres of more than 20 JDF units had significantly decreased proportions of CD3 cells. This reduction was predominantly in the CD4 subset, giving rise to a decreased CD4/CD8 lymphocyte ratio. Those with ICA titres between 5 and 20 JDF units showed abnormalities in both CD3 and CD4 lymphocytes, but not in CD4/CD8 lymphocyte ratio. Further characterization of the CD4 cell subset was performed using three other monoclonal antibodies, CD45RO (UCHL1), CD45RA and CD29, phenotyping memory T-cells, the inducer cells of suppressor function and helper-inducer cells, respectively. The proportions of total CD45RO and CD45RA were not significantly different among first-degree relative with distinct ICA titres in a cross-sectional study, whereas a trend towards a reduced proportion of CD4/CD45RA cells was observed. The longitudinal study demonstrated that individuals potentially susceptible to the development of type 1 diabetes and who possess high titres of ICA have impairment of CD4/CD8 lymphocyte ratio, mainly due to a reduction in the CD4 subset.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1533543     DOI: 10.1007/bf00778996

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  17 in total

1.  Assessment of precision, concordance, specificity, and sensitivity of islet cell antibody measurement in 41 assays.

Authors:  E Bonifacio; C Boitard; H Gleichmann; M A Shattock; J L Molenaar; G F Bottazzo
Journal:  Diabetologia       Date:  1990-12       Impact factor: 10.122

2.  Do CD4-positive cytotoxic T cells damage islet beta cells in type 1 diabetes?

Authors:  P de Berardinis; M Londei; R F James; S P Lake; P H Wise; M Feldmann
Journal:  Lancet       Date:  1988-10-08       Impact factor: 79.321

3.  Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies.

Authors:  G F Bottazzo; A Florin-Christensen; D Doniach
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

Review 4.  Mechanisms of autoimmunity: relevance to the pathogenesis of type I (insulin-dependent) diabetes mellitus.

Authors:  E Bosi; I Todd; R Pujol-Borrell; G F Bottazzo
Journal:  Diabetes Metab Rev       Date:  1987-10

5.  Persistent reduction of CD4/CD8 lymphocyte ratio and cell activation before the onset of type 1 (insulin-dependent) diabetes.

Authors:  L Al-Sakkaf; P Pozzilli; A C Tarn; G Schwarz; E A Gale; G F Bottazzo
Journal:  Diabetologia       Date:  1989-05       Impact factor: 10.122

6.  Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases.

Authors:  R K Sibley; D E Sutherland; F Goetz; A F Michael
Journal:  Lab Invest       Date:  1985-08       Impact factor: 5.662

Review 7.  Novel considerations on the antibody/autoantigen system in type I (insulin-dependent) diabetes mellitus.

Authors:  G F Bottazzo; S Genovese; E Bosi; B M Dean; M R Christie; E Bonifacio
Journal:  Ann Med       Date:  1991-10       Impact factor: 4.709

8.  Complement-fixing islet-cell antibodies in type-I diabetes: possible monitors of active beta-cell damage.

Authors:  G F Bottazzo; B M Dean; A N Gorsuch; A G Cudworth; D Doniach
Journal:  Lancet       Date:  1980-03-29       Impact factor: 79.321

9.  Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes.

Authors:  E Bonifacio; P J Bingley; M Shattock; B M Dean; D Dunger; E A Gale; G F Bottazzo
Journal:  Lancet       Date:  1990-01-20       Impact factor: 79.321

10.  Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex.

Authors:  T Matsuyama; A Yamada; J Kay; K M Yamada; S K Akiyama; S F Schlossman; C Morimoto
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

View more
  5 in total

Review 1.  The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure.

Authors:  Bart O Roep
Journal:  Diabetologia       Date:  2003-03-22       Impact factor: 10.122

2.  Importance of persistent cellular and humoral immune changes before diabetes develops: prospective study of identical twins.

Authors:  R Y Tun; M Peakman; L Alviggi; M J Hussain; S S Lo; M Shattock; D A Pyke; G F Bottazzo; D Vergani; R D Leslie
Journal:  BMJ       Date:  1994-04-23

3.  Variable immune cell frequencies in peripheral blood of LEW.1AR1-iddm rats over time compared to other congenic LEW strains.

Authors:  T Arndt; A Jörns; H-J Hedrich; S Lenzen; D Wedekind
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

4.  eIF5A inhibition influences T cell dynamics in the pancreatic microenvironment of the humanized mouse model of Type 1 Diabetes.

Authors:  Shahnawaz Imam; R Prathibha; Pervaiz Dar; Khalil Almotah; Ahmed Al-Khudhair; Syed Abdul-Moiz Hasan; Nancy Salim; Talha Naser Jilani; Raghavendra G Mirmira; Juan Carlos Jaume
Journal:  Sci Rep       Date:  2019-02-07       Impact factor: 4.379

5.  A variable CD3⁺ T-cell frequency in peripheral blood lymphocytes associated with type 1 diabetes mellitus development in the LEW.1AR1-iddm rat.

Authors:  Tanja Arndt; Anne Jörns; Heike Weiss; Markus Tiedge; Hans-Jürgen Hedrich; Sigurd Lenzen; Dirk Wedekind
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.